CEP-18770

Base Information

Chemical Name:CEP-18770
CAS No.:847499-27-8
Molecular Formula:C₂₁H₂₈BN₃O₅
Molecular Weight:413.281
Hs Code.:29333990
Mol file:847499-27-8.mol

Synonyms:CEP 18770;CEP-18770;

Suppliers and Price of CEP-18770

Supply Marketing:

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

Usbiological
Delanzomib
5mg
$ 602.00

TRC
Delanzomib
200mg
$ 2270.00

Medical Isotopes, Inc.
Delanzomib
200 mg
$ 3400.00

DC Chemicals
Delanzomib(CEP-18770) >98%
100 mg
$ 500.00

DC Chemicals
Delanzomib(CEP-18770) >98%
1 g
$ 1900.00

ChemScene
Delanzomib ≥98.0%
100mg
$ 1152.00

ChemScene
Delanzomib ≥98.0%
5mg
$ 150.00

ChemScene
Delanzomib ≥98.0%
10mg
$ 276.00

ChemScene
Delanzomib ≥98.0%
50mg
$ 780.00

Cayman Chemical
Delanzomib ≥95%
50mg
$ 811.00

Total 51 raw suppliers

Chemical Property of CEP-18770

Chemical Property:

Appearance/Colour:white powder
PKA:9.67±0.43(Predicted)
PSA：138.76000
Density:1.207
LogP:2.60570
Storage Temp.:Hygroscopic, -20°C Freezer, Under Inert Atmosphere
Solubility.:Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Slightly)

Purity/Quality:

99% ^*data from raw suppliers

Delanzomib ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Description Delanzomib is an orally bioavailable inhibitor of chymotrypsin-like proteasome activity (IC50 = 3.8 nM in isolated human erythrocytes) that only marginally inhibits tryptic and peptidyl glutamyl proteasome activity. Delanzomib pre-treatment (20 nM) in vitro inhibits IκBα degradation, NF-κB activation, and the expression of NF-κB-regulated genes, including IκBα, XIAP, TNF-α, IL-1β, ICAM-1, and VEGF. Delanzomib induces apoptosis in multiple myeloma cell lines and inhibits proliferation in a panel of human hematologic and solid tumor cell lines (IC50s = 5.6-34.2 nM). It reduces tumor weight in an RPMI 8226 human multiple myeloma mouse xenograft model when administered intravenously at doses ranging from 1.5-4 mg/kg twice daily and leads to complete tumor regression at a chronic oral dose of 13 mg/kg. Delanzomib reduces the serum level of circulating cytokines, prevents renal tissue damage, and increases lifespan in a mouse model of fatal lupus nephritis.
Uses Delanzomib is an orally active proteasome inhibitor. Delanzomib has been shown to down-modulate NF-κB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.

Technology Process of CEP-18770

There total 8 articles about CEP-18770 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 90.0%